245 related articles for article (PubMed ID: 30864705)
1. Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer.
Feng Y; Hang W; Sang Z; Li S; Xu W; Miao Y; Xi X; Huang Q
Mol Med Rep; 2019 May; 19(5):3376-3392. PubMed ID: 30864705
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-145-5p in cancer cells and their derived exosomes may contribute to the development of ovarian cancer by targeting CT.
Hang W; Feng Y; Sang Z; Yang Y; Zhu Y; Huang Q; Xi X
Int J Mol Med; 2019 Jan; 43(1):256-266. PubMed ID: 30365097
[TBL] [Abstract][Full Text] [Related]
4. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
5. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
6. Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer.
Xin Y; Wang X; Meng K; Ni C; Lv Z; Guan D
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31763681
[TBL] [Abstract][Full Text] [Related]
7. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
8. Screening of exosomal miRNAs derived from subcutaneous and visceral adipose tissues: Determination of targets for the treatment of obesity and associated metabolic disorders.
Yang Z; Wei Z; Wu X; Yang H
Mol Med Rep; 2018 Sep; 18(3):3314-3324. PubMed ID: 30066923
[TBL] [Abstract][Full Text] [Related]
9. Exosomal release of microRNA-454 by breast cancer cells sustains biological properties of cancer stem cells via the PRRT2/Wnt axis in ovarian cancer.
Wang L; He M; Fu L; Jin Y
Life Sci; 2020 Sep; 257():118024. PubMed ID: 32598931
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
[TBL] [Abstract][Full Text] [Related]
11. Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells.
Zhang S; Zhang X; Fu X; Li W; Xing S; Yang Y
Oncol Lett; 2018 Aug; 16(2):2391-2401. PubMed ID: 30013629
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
Rashed MH; Kanlikilicer P; Rodriguez-Aguayo C; Pichler M; Bayraktar R; Bayraktar E; Ivan C; Filant J; Silva A; Aslan B; Denizli M; Mitra R; Ozpolat B; Calin GA; Sood AK; Abd-Ellah MF; Helal GK; Berestein GL
Oncotarget; 2017 Mar; 8(12):20145-20164. PubMed ID: 28423620
[TBL] [Abstract][Full Text] [Related]
13. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
Ruan L; Xie Y; Liu F; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
15. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
16. Exosomal microRNA‑146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2‑mediated PI3K/Akt axis.
Qiu L; Wang J; Chen M; Chen F; Tu W
Int J Mol Med; 2020 Aug; 46(2):609-620. PubMed ID: 32626953
[TBL] [Abstract][Full Text] [Related]
17. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.
Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776
[TBL] [Abstract][Full Text] [Related]
18. Identification of key microRNAs and their targets in exosomes of pancreatic cancer using bioinformatics analysis.
Zhao X; Ren Y; Cui N; Wang X; Cui Y
Medicine (Baltimore); 2018 Sep; 97(39):e12632. PubMed ID: 30278585
[TBL] [Abstract][Full Text] [Related]
19. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
20. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
